Prevalence of target organ damage in treated hypertensive patients: Different impact of clinic and ambulatory blood pressure control

Journal of Hypertension

Volumn 18, Issue 6, 2000, Pages 803-809

  Cuspidi, Cesare ^a   Lonati, Laura ^b   Sampieri, Lorena ^b   Michev, Lassen ^b   Macca, Giuseppe ^b   Rocanova, José I ^b   Salerno, Maurizio ^b   Fusi, Veronica ^b   Leonetti, Gastone ^b   Zanchetti, Alberto ^b  

^a Ctro Fisiol Clinica e Ipertensione   (Italy)

^b NONE

Author keywords

Clinic and ambulatory blood pressure control; Hypertension; Left ventricular hypertrophy; Microalbuminuria

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CHOLESTEROL; CREATININE; GLUCOSE;

ADULT; AGE; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; BODY SURFACE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; OBESITY; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; SMOKING; TARGET ORGAN; URINARY EXCRETION;

EID: 0034043114     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018060-00020     Document Type: Article

References (34)

1. 1 Burt VL, Cutler YA, Higgins M, Horan MY, Labarthe D, Whelton P, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adults US population. Data from the health examination surveys 1960-1991. Hypertension 1995; 26:60-65.
2. 2 Mancia G, Sega R, Milesi C, Cesana S, Zanchetti A. Blood pressure control in the hypertension population. Lancet 1997; 348:454-457.
3. 3 Colhoun HM, Doug W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England. J Hypertens 1998; 16:747-752.
4. 4 Zanchetti A. Contribution of fixed low-dose combinations to initial therapy in hypertension. Eur Heart J 1999; 1 (Suppl L):L5-L9.
5. 5 Samuelsson O, Wihelmsen L, Elmfeldt K, Wedel H, Wikstrand Y, Berglung G, et al. Predictors of cardiovascular morbidity in treated hypertensives: results from the primary prevention trial in Goteborg, Sweden. J Hypertens 1985; 3:167-176.
6. 6 Lindholm L, Ejertsson G, Schersten B. High risk of cerebrovascular morbidity in well treated male hypertensives. Arch Med Scand 1984; 216:251-259.
7. 7 Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24 hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 1987; 5:93-98.
8. 8 Giaconi S, Levanti C, Fommei E, Innocenti F, Seghieri S, Palla L, et al. Microalbuminuria and casual and ambulatory blood pressure monitoring in normotensives and in patients with borderline and mild hypertension. Am J Cardiol 1989; 2:259-261.
9. 9 Shimada K, Kawamoto A, Matsubayaski K, Nashinaga M, Kimura S, Tzawa T. Diurnal blood pressure variations and silent cerebrovasoular damage in elderly patients with hypertension. J Hypertens 1992; 10:875-878.
10. 10 Perloff D, Solokow M, Cowan R. The prognostic value of ambulatory blood pressure monitoring in treated hypertensive patients. J Hypertens 1991; 9(Suppl 1):S33-S40.
11. 11 Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood variability. J Hypertens 1993; 11:1133-1137.
12. 12 Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciuoci A, Battistelli M, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
13. 13 Mancia G, Zanchetti A, Agabiti Rosei E, Benemio G, De Cesaris R, Fogari R, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95:1464-1470.
14. 14 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines subcommittee. J Hypertens 1999; 17:151-183.
15. 15 Mancia G, Sega R, Bravi C, De Vito G, Valagussa F, Cesana G, et al. Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995; 13:1337-1390.
16. 16 Devereux RB, Reichek W. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1997; 55:613-618.
17. 17 Hammond I, Devereux RB, Alderman M, Lutas E, Spitzer M, Crowley J, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7:639-650.
18. 18 Koren MG, Devereux RB, Casale PN, Savage DD, Laragh JM. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:343-352.
19. 19 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
20. 20 Ganau A, Devereux RB, Roman RJ, de Simone G, Pickering TG, Saba PG, et al. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-1558.
21. 21 Frohlich ED, Apstein C, Chobanian AM, Ducreux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med 1992; 327:998-1008.
22. 22 Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 1987; 59:956-960.
23. 23 Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in a general population. The Tromso Study. Eur Heart J 1999; 20:429-438.
24. 24 Gamble G, MacMahon S, Culpan A, Ciobo C, Whalley G, Sharpe M. Atherosclerosis and left ventricular hypertrophy: persisting problems in treated hypertensive patients. J Hypertens 1998; 16:1389-1395.
25. 25 Cuspidi C, Lonati L, Sampieri L, Macca G, Valagussa L, Zaro T, et al. Blood pressure control in a hypertension hospital clinic. J Hypertens 1999; 17:835-841.
26. 26 Agewall S, Wilkstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1997; 80:164-169.
27. 27 Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14:223-228.
28. 28 Cerasola G, Cottone S, Mulé G, Nardi E, Mangano MT, Andronico G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14:915-920.
29. 29 Nishijo M, Nakagawa H, Morikawa Y, Miura K, Tabata M, Ishizaki M. Microalbuminuria and hypertension in non diabetic Japanese men. Am J Hypertens 1999; 12:16-20.
30. 30 Pontremoli R, Nicolella C, Viazzi F, Ravera M, Sofia A, Bezante V, et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998; 11:430-438.
31. 31 Palatini P, Mormino P, Santonastaso M, Mos L, Dal Follo M, Zanata G, Pessina AC, on behalf of the HARVEST Study Investigators. Target organ damage in stage I hypertensive subjects with white coat and sustained hypertension. Results from the HARVEST Study. Hypertension 1998; 31:57-63.
32. 32 Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Cluasen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factor. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11:727-732.
33. 33 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996; 78:197-202.
34. 34 Rizzon D, Muiesan ML, Montani G, Zulli R, Calebich S, Agabiti Rosei E. Relationship between initial cardiovascular structural changes and daytime and night-time blood pressure monitoring. Am J Hypertens 1992; 5:180-186.